Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN N.V. (NYSE: QGEN) has announced the release of its fourth quarter and full-year 2020 results on February 9, 2021, at 22:05 CET / 16:05 EST. A conference call will take place on February 10, at 15:00 CET / 9:00 EST, hosted by CEO Thierry Bernard and CFO Roland Sackers. Interested participants can join the call via phone or access a live webcast. For convenience, it's recommended to join the conference 5-10 minutes early. QGEN's solutions support molecular diagnostics and life sciences, serving over 500,000 customers globally.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) plans to resubmit its QIAreach SARS-CoV-2 Antigen Test to the U.S. FDA for Emergency Use Authorization in Q1 2021 after withdrawing its initial submission in November 2020 due to a chemistry-related issue. The company believes the issue has been resolved and is currently collecting data for resubmission. QIAGEN's CEO, Thierry Bernard, emphasized their commitment to expediting the process to assist in COVID-19 testing. Despite this, the company does not expect any impact on its full-year 2021 sales or adjusted earnings.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) confirmed that its PCR tests for SARS-CoV-2 remain effective against known viral variants. Since May 2020, assessments of the tests against genetic mutations have shown no impact on sensitivity. The company will continue biweekly surveillance of genetic variations. Chief Medical Officer Davide Manissero emphasized the importance of genomic sequencing in monitoring the virus. The report highlights variants like VUI 202012/01, 501Y.V2, and B.1.1.28 P1, which pose increased transmissibility risks.
QIAGEN has appointed Dr. Toralf Haag to its Supervisory Board effective immediately, expanding its membership to seven. Haag, who also joins the Audit Committee, brings extensive experience from his roles in leading companies like Voith and Lonza Group. This strategic move aims to enhance the Board's expertise in Life Sciences and diagnostics. The appointment is part of a broader review process initiated in 2020 aimed at strengthening corporate governance and maximizing stakeholder value.
Summary not available.
QIAGEN N.V. (QGEN) has successfully priced new senior, unsecured convertible bonds totaling $500 million, due in 2027. The bonds, with an initial conversion price set at $80.7218 per share, will be issued at 100% of their principal amount and pay no interest. Concurrently, the company is repurchasing $172.8 million of outstanding convertible notes due in 2021. The proceeds from the new bonds will be used for the repurchase and general corporate purposes. Settlement for both transactions is expected on December 17, 2020.
QIAGEN (NYSE: QGEN) has raised its full-year 2020 forecast for net sales and adjusted earnings per share, anticipating strong performance in 2021 driven by its focus on five growth pillars. The company also plans to expand its Supervisory Board to enhance expertise in Life Sciences and diagnostics. CEO Thierry Bernard acknowledged the team's efforts during the COVID-19 pandemic, highlighting the launch of new testing solutions and increased production capacity. QIAGEN will host a Virtual Deep Dive on December 8 for a strategic and financial update.
QIAGEN N.V. has launched the QuantiFERON SARS-CoV-2 RUO solution, designed to detect T-cell responses to COVID-19. This innovative technology enables researchers to assess immunity levels and disease progression more effectively, as studies show T-cell responses decline slower than antibody responses. With the ability to indicate disease severity and long-term immunity, this tool enhances QIAGEN's COVID-19 portfolio, which includes sample-preparation technology and PCR testing.
QIAGEN N.V. has entered a strategic collaboration with BioNTech SE to develop a tissue-based companion diagnostic for identifying patients with head and neck squamous cell carcinoma (SCCHN) linked to human papilloma virus (HPV) infections. Utilizing QIAGEN’s RGQ MDx platform, the assay aims to expand its applications across various HPV-related cancers. With over 650,000 new SCCHN cases annually, and projections indicating doubled numbers by 2035, this collaboration positions QIAGEN to enhance its HPV diagnostic offerings, building on its established market leadership.
QIAGEN N.V. (NYSE: QGEN) has launched the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test in Europe, addressing the need for rapid diagnosis during flu season. This multiplex PCR test can differentiate between influenza A and B, RSV, and SARS-CoV-2 in just 80 minutes, aiding healthcare professionals in treatment decisions amidst similar respiratory symptoms. Following CE-IVD registration, the test has also received a request for Emergency Use Authorization from the FDA. The company has additionally expanded the use of saliva samples in its existing SARS-CoV-2 test.